Proactive Investors - Run By Investors For Investors

ValiRx puts convertible loan note facility with Yorkville to bed

ValiRx confirms that there are no further obligations existing between itself and Yorkville
Bank roll
The company's issued share capital will comprise of 399mln shares on admission of the 25.2mln shares to YA II.

Cancer therapeutics specialist ValiRx Plc (LON:VAL) said its standby equity distribution agreement with Yorkville (YA) is now done and dusted.

YA elected to convert all remaining US$520,000 of its convertible loan notes from the second tranche of its loan facility into 25.2mln ValiRx shares at a conversion price of 1.5429p a share.

No further amounts on Tranche 2 of the convertible loan notes (CLNs) remain outstanding. As previously announced Tranches 1 and 3 have been fully repaid and so this is the final conversion under the CLN facility.  

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

cancer cells
December 15 2017
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
IPF chart
December 14 2017
The new terms give it the opportunity to benefit from a partnership across a whole range of fibrosis-focused treatments
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use